Manager TitleAgeSince
President - 30/07/2025
Compliance Officer - -
Chief Tech/Sci/R&D Officer - -
Change 5-day change 1-year change 3-year change Capi.($)
+2.12%+2.57% - - 1.8B
+0.41%-2.75%+50.30%+89.43% 1,002B
-0.12%-2.45%+51.71%+65.04% 649B
+0.40%-4.56%+18.71%+67.59% 440B
-0.76%-0.37%+29.00%+37.02% 346B
-0.09%-14.97%+9.41%+26.44% 263B
-1.80%-2.59%-2.59%+11.08% 250B
+0.01%-11.26%+40.37%+50.15% 213B
-1.06%-4.23%-14.70%-57.76% 201B
-0.12%-2.36%+26.19%+89.61% 182B
Average -0.13%-2.06%+23.15%+42.07% 393.74B
Weighted average by Cap. -0.17%-2.39%+32.28%+56.26%
Logo Endo, Inc.
Endo, Inc. is a diversified specialty pharmaceutical company, which is engaged in transforming insights into life-enhancing therapies. The Company’s segments include Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Its Branded Pharmaceuticals segment focuses on products that have inherent scientific, regulatory, legal and/or technical complexities and are marketed under recognizable brand names that are trademarked. Its Sterile Injectables segment includes a broad portfolio of approximately 40 critical care, maternal health, anesthesia and other products. Its Generic Pharmaceuticals segment includes a portfolio of approximately 85 generic product families, including solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, and others. Its International Pharmaceuticals segment sells a variety of specialty pharmaceutical products outside the United States, primarily to customers in Canada.
Employees
3,116
  1. Stock Market
  2. Stocks
  3. NDOI Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!